NEVVI Medicare utilization intelligence

← back

SHREEDHARA VASUDHA, MEERAMD NPI 1639388689 Clinician

Medical Oncology · GREENVILLE, TX

Specialty Medical Oncology — from billed Medicare claims
In practice about 26 years since medical school (class of 2000, self-reported to CMS)
Location GREENVILLE, TX · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 43 codes billed · 102,217 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
TEXAS ONCOLOGY PA
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2021-03

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1756 Injection, iron sucrose, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1453 Injection, fosaprepitant, 1 mg
J9267 Injection, paclitaxel, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
J1437 Injection, ferric derisomaltose, 10 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J1626 Injection, granisetron hydrochloride, 100 mcg
96375 Injection of additional new drug or substance into vein
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
96372 Injection of drug or substance under skin or into muscle
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96417 Administration of additional new drug or substance into vein, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J3490 Unclassified drugs
96374 Injection of drug or substance into vein
96523 Irrigation of implanted venous access drug delivery device
J7030 Infusion, normal saline solution , 1000 cc
96411 Administration of additional new drug or substance into vein using push technique
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96361 Infusion into a vein for hydration, each additional hour
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
96360 Infusion into a vein for hydration, 31-60 minutes
99195 Drawing of blood for a medical problem
99202 New patient office or other outpatient visit with straightforward medical decision making, if using time, 15 minutes or more
G0008 Administration of influenza virus vaccine
90653 Influenza vaccine, inactivated

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.